ROLE OF DOSE-INTENSITY OF NEOADJUVANT CHEMOTHERAPY AND COMPLIANCE WITH COMPLETE PATHOLOGICAL REPORT
Sumaiya Tabassum*, Armughan Aymen Mastan, Mohammed Anasullah, Dr. Raghu ram, Dr. Anupama Koneru, Dr. K Suseela and Dr. Rakesh Pinniti
ABSTRACT
The purpose of this study is to understand the patterns of neoadjuvant chemotherapy utilization in TNBC and factors that facilitate in improving the response rate, toxicities and compliances. Triple negative breast cancer represents cancer cells that lack progesterone receptors, estrogen receptors as well as the protein called HER2, the tumor primarily starting in the breast, with the metastasis expected to effect the brain and the lungs. In this study, we reviewed the treatment patterns for TNBC and factors that facilitate in improving the response rate, toxicities and compliances. A retrospective observational study was carried out at Basavatarakam Indo American Cancer Hospital, Hyderabad, Telangana. A total of 150 case files of patients of TNBC were evaluated in the study for a duration of 6 months. The parameters included in the evaluation were, A chi-square test of individuality presented that there was a substantial association between the percentage of subjects who reported to show a Pathological complete response and who receive a combination of Anthracycline and cyclophosphamide and paclitaxel. By the best recommendation by the physician and in accordance with the patient preferences to receive which type of treatment we can strive to improve the quality of life. Although chemotherapy is known to have adverse effects by receiving Supportive therapy, we can manage the adverse drug effects and arrest the progression of triple-negative breast cancer.
Keywords: Triple-negative breast cancer, anthracycline chemotherapy, taxanes.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
